Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report

BACKGROUND: Immune checkpoint inhibitors, including programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) have recently been approved to treat locally advanced and metastatic urothelial carcinoma (UC). However, some patients experience rapid tumor progression rather than any clinical benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hong-Yu, Du, Yu-Xuan, Hou, Yu-Jia, Lu, Dian-Rong, Xue, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600846/
https://www.ncbi.nlm.nih.gov/pubmed/37901032
http://dx.doi.org/10.12998/wjcc.v11.i28.6841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600846/
https://www.ncbi.nlm.nih.gov/pubmed/37901032
http://dx.doi.org/10.12998/wjcc.v11.i28.6841

Ejemplares similares